TachoSil | Jotup

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

Retrieved on:

Wednesday, April 26, 2023

Surgeon, Surgery, Takeda, GTCR, TAK, TachoSil, Takeda Pharmaceutical Company, Francisco Corzas, Acquisition, FDI, Patient, Maggot therapy, Growth, Health, Pharmaceutical industry

WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients. 

Key Points:

WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria.
Corza Medical had previously acquired the commercial product rights for TachoSil , a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021.
Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients.
“We look forward to welcoming the Takeda TachoSil operations team to Corza Medical to support our investment in expanding manufacturing capacity, testing systems, and R&D facilities to develop new Biosurgery offerings,” said Tom Testa, Corza Medical Chief Executive Officer.

Corza Medical Announces Direct Distribution of TachoSil® to the US Market

Retrieved on:

Thursday, April 20, 2023

Surgeon, Atmosphere, TachoSil, Thrombin, Fibrinogen, Hemostasis, Patient, Fibrin, Baxter International, SVP, Pharmaceutical industry, Nursing, Takeda

WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023.

Key Points:

WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023.
Corza Medical acquired TachoSil in January 2021 from Takeda, who previously had Baxter Healthcare distribute TachoSil exclusively in the U.S. market.
Corza Medical ended the agreement effective March 31, 2023.
“Distributing TachoSil directly to customers in the U.S. market demonstrates our commitment to advancing and growing this renowned product,” said Tom Testa Corza Medical CEO.

Corza Medical Expands Global Leadership Team

Retrieved on:

Monday, January 9, 2023

Maggot therapy, Getty, Doctor of Philosophy, Surgery, Takeda Pharmaceutical Company, GE, GTCR, Simmons, Growth, Novena Global Lifecare, Cardinal Health, GE Healthcare, TachoSil, Senior, Leclercq, Management, Ophthalmology

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.

Key Points:

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.
"Corza Medical is intensely focused on making every customer interaction remarkable, earning client's trust through our high-quality technologies, and delivering outstanding value.
With the foundation of Corza Medical now established, we are excited to announce the next level of leadership reporting to chief executive officer, Tom Testa," said Gregory T. Lucier, Executive Chairman of Corza Medical.
"Having built the foundation of the company the last two years, we are excited with these additions to our outstanding leadership team as we now move our focus to transformational growth," said Tom Testa, CEO of Corza Medical.

Corza Medical Expands Global Leadership Team

Retrieved on:

Monday, January 9, 2023

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.

Key Points:

WESTWOOD, Mass., Jan. 9, 2023 /PRNewswire/ -- Corza Medical has announced key additions to the global leadership team as the company builds for the next phase of growth.
"Corza Medical is intensely focused on making every customer interaction remarkable, earning client's trust through our high-quality technologies, and delivering outstanding value.
With the foundation of Corza Medical now established, we are excited to announce the next level of leadership reporting to chief executive officer, Tom Testa," said Gregory T. Lucier, Executive Chairman of Corza Medical.
"Having built the foundation of the company the last two years, we are excited with these additions to our outstanding leadership team as we now move our focus to transformational growth," said Tom Testa, CEO of Corza Medical.

Corza Medical Announces Key Executive Appointments

Retrieved on:

Tuesday, December 6, 2022

Ecosystem, GTCR, Israel Advanced Technology Industries, CFO, Blinking, Nordson Corporation, Takeda Pharmaceutical Company, Investment, Pleasure, Growth, Surgery, Fibrin, Quill, TachoSil, Acquisition, Management, Francisco Corzas

WESTWOOD, Mass, Dec. 6, 2022 /PRNewswire/ -- Corza Medical ("Corza" or the "Company") announced today that it has appointed Tom Testa to the role of Chief Executive Officer and member of the Board of Directors. A current member of the Corza leadership team, Mr. Testa has served as Chief Financial Officer of the Company since GTCR's investment in 2021. Retiring Corza CEO Dan Croteau will directly support Mr. Testa during this leadership transition and continue to serve on the Board of Directors of the Company going forward, alongside Executive Chairman and founder Gregory Lucier, among others. In addition, Corza has appointed Henry Burmeister to the role of Chief Financial Officer. Both executive appointments are effective in January 2023. Corza's founder and Executive Chairman Gregory T. Lucier will continue to guide the Company's long-term strategy.

Key Points:

Prior to Corza, he served as Vice President, General Manager of Nordson Corporation's standalone Nordson Medical business, a leading global integrated solutions provider for the medical device industry with 15 facilities globally.
Mr. Burmeister joins Corza with more than 20 years of experience in financial leadership roles in the medical device and specialty chemicals sectors.
Prior to Wytech Industries, Mr. Burmeister held senior finance roles at Viant Medical and Vention Medical, where he worked closely with Mr. Testa.
Corza Medical is a portfolio company of GTCR, a leading private equity firm, which helped create and build the business alongside Mr. Lucier.

Corza Medical Announces Dennis Crowley as Executive Vice President, Corporate Development

Retrieved on:

Tuesday, January 4, 2022

WESTWOOD, Mass., Jan. 4, 2022 /PRNewswire/ -- Corza Medical ("Corza"), a leading global manufacturer of innovative surgical technologies, today announced the expansion of its leadership team with the addition of Dennis Crowley as Executive Vice President, Corporate Development.

Key Points:

WESTWOOD, Mass., Jan. 4, 2022 /PRNewswire/ -- Corza Medical ("Corza"), a leading global manufacturer of innovative surgical technologies, today announced the expansion of its leadership team with the addition of Dennis Crowley as Executive Vice President, Corporate Development.
Mr. Crowley brings nearly thirty years of experience in strategy and business development, driving organic and acquired growth through mergers and acquisitions, joint ventures and strategic affiliations.
"I'm thrilled to welcome Dennis to the Corza Medical team, as his industry experience will be a tremendous asset to the ongoing expansion of the business," said Lucier.
"Corza Medical is a company with a strong growth trajectory," said Crowley.